CELL AND GENE THERAPY INSIGHTS

Filter by ContentType

‘Winning’ target product profiles for CAR-T cell therapies in oncology: critical success factors for commercially viable therapies

‘Winning’ target product profiles for CAR-T cell therapies in oncology: critical success factors for commercially viable therapies

Clare Hague, Louise Street-Docherty, Frances Pearson
19 December 2024
Expert Insight
 Automated plasmid assembly: a perspective from early drug discovery

Automated plasmid assembly: a perspective from early drug discovery

S Ahammu, J Chi, T Edström et al
18 December 2024
Expert Insight
 Interpreting the new FDA draft potency guidance: an RNA cell therapy perspective

Interpreting the new FDA draft potency guidance: an RNA cell therapy perspective

Damian Marshall, Kayleigh Thirlwell
02 December 2024
Expert Insight
 Operations strategy for a scalable CGT supply chain: key CXO insights

Operations strategy for a scalable CGT supply chain: key CXO insights

Shesh Sharma, Tim Sirichoke, Edward Ballesteros
02 December 2024
Expert Insight
 Revolutionizing the treatment of cancer with allogeneic CAR-T cell therapy

Revolutionizing the treatment of cancer with allogeneic CAR-T cell therapy

Cokey Nguyen
13 November 2024
Expert Insight
 Enhancing AAV process quality and efficiency: three case studies highlighting the benefits of upgraded analytics on downstream process development

Enhancing AAV process quality and efficiency: three case studies highlighting the benefits of upgraded analytics on downstream process development

E Hudspeth, I Green, T Dewosky et al
11 November 2024
Expert Insight
 Challenges encountered when delivering advanced therapy investigational medicinal products in the National Health Service in the UK: a pharmacy perspective

Challenges encountered when delivering advanced therapy investigational medicinal products in the National Health Service in the UK: a pharmacy perspective

B Amirloo, B Duran, I Sanna et al
29 October 2024
Expert Insight
 Analytics for cell and gene therapy products in early development: points to consider before preparing an IND for a first-in-human clinical trial

Analytics for cell and gene therapy products in early development: points to consider before preparing an IND for a first-in-human clinical trial

William E Janssen, Scott Burger
15 October 2024
Expert Insight
 Therapeutic epigenome editing: safety and quality considerations of a new class of gene-targeted medicines

Therapeutic epigenome editing: safety and quality considerations of a new class of gene-targeted medicines

Houria Bachtarzi, Tim Farries
15 October 2024
Expert Insight
 The cell therapy industrial revolution: current successes, existing challenges, and expansion into new domains

The cell therapy industrial revolution: current successes, existing challenges, and expansion into new domains

Joel Gaston, Matthew Li
24 September 2024
Expert Insight
 Patient-specific factors that could influence gene therapy outcomes in sickle cell disease

Patient-specific factors that could influence gene therapy outcomes in sickle cell disease

Abdulrahman Alsultan, Jaap Jan Boelens
02 September 2024
Expert Insight
 Upstream processing of viral vectors: a summary

Upstream processing of viral vectors: a summary

Pardhasaradhi Mathi
29 July 2024
Expert Insight
 MHRA regulatory considerations for the quality of mRNA products

MHRA regulatory considerations for the quality of mRNA products

Ka-Wai Wan, Francis Galaway
22 May 2024
Expert Insight
 The sweet cell of success: key considerations for the sourcing and production of pluripotent cell lines for therapeutic development

The sweet cell of success: key considerations for the sourcing and production of pluripotent cell lines for therapeutic development

Samuel JI Blackford, Nathan C Manley
21 May 2024
Expert Insight
 Raw materials and supplies for cell therapies: end to end expectations and best practices

Raw materials and supplies for cell therapies: end to end expectations and best practices

Lili Belcastro
15 May 2024
Expert Insight
 Are we there yet? After 250+ AAV-based clinical trials, do we have a well-paved road toward first-in-human entry?

Are we there yet? After 250+ AAV-based clinical trials, do we have a well-paved road toward first-in-human entry?

Long Chen, Chia Chu, Francesca Vitelli
10 May 2024
Expert Insight
 Improving process efficiency to reduce cost-of-goods per dose in manufacturing of recombinant AAVs

Improving process efficiency to reduce cost-of-goods per dose in manufacturing of recombinant AAVs

G Thakur, S Mink, H Bak et al
03 May 2024
Expert Insight
 Innovation in hematopoietic stem cell cryopreservation and cold chain management

Innovation in hematopoietic stem cell cryopreservation and cold chain management

M Prisciandaro, M Santodirocco, G Fania et al
30 April 2024
Expert Insight
 Preclinical trends in developing genetically altered cell therapies

Preclinical trends in developing genetically altered cell therapies

Mary Ellen Cosenza
25 March 2024
Expert Insight
 Challenges and advances of the stability of mRNA delivery therapeutics

Challenges and advances of the stability of mRNA delivery therapeutics

Jin Zhai, Trystin Cote, Yupeng Chen
13 March 2024
Expert Insight
 A straightforward tool for developing a raw material supply strategy for cell & gene therapies

A straightforward tool for developing a raw material supply strategy for cell & gene therapies

K Kulenkampff, R Eigenmann, D Karlstetter et al
08 January 2024
Expert Insight